Jacobs Levy Equity Management Inc. Acquires 120,699 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Jacobs Levy Equity Management Inc. boosted its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX) by 29.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 524,861 shares of the biopharmaceutical company’s stock after acquiring an additional 120,699 shares during the quarter. Jacobs Levy Equity Management Inc. owned 0.34% of TG Therapeutics worth $7,983,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TGTX. Pingora Partners LLC bought a new stake in TG Therapeutics during the fourth quarter worth about $27,000. Lazard Asset Management LLC bought a new stake in TG Therapeutics during the first quarter worth about $91,000. NBC Securities Inc. lifted its position in shares of TG Therapeutics by 34.5% during the fourth quarter. NBC Securities Inc. now owns 9,401 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 2,409 shares in the last quarter. Private Portfolio Partners LLC acquired a new position in shares of TG Therapeutics during the fourth quarter worth approximately $201,000. Finally, Private Advisor Group LLC acquired a new position in shares of TG Therapeutics during the fourth quarter worth approximately $233,000. Institutional investors own 58.58% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. reiterated an “overweight” rating and set a $25.00 target price on shares of TG Therapeutics in a research report on Thursday, April 18th. HC Wainwright upped their target price on shares of TG Therapeutics from $45.00 to $49.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, LADENBURG THALM/SH SH upped their target price on shares of TG Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $29.83.

TG Therapeutics Stock Down 3.0 %

Shares of TGTX stock traded down $0.60 during trading hours on Tuesday, hitting $19.21. 2,800,766 shares of the company were exchanged, compared to its average volume of 3,639,129. The business has a 50 day moving average of $18.28 and a two-hundred day moving average of $16.41. The company has a current ratio of 3.62, a quick ratio of 2.84 and a debt-to-equity ratio of 0.63. TG Therapeutics, Inc. has a 52 week low of $6.46 and a 52 week high of $23.12. The company has a market capitalization of $2.97 billion, a PE ratio of 86.13 and a beta of 2.23.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The business had revenue of $63.47 million during the quarter, compared to the consensus estimate of $54.60 million. TG Therapeutics had a net margin of 14.24% and a return on equity of 31.34%. The firm’s revenue for the quarter was up 713.5% on a year-over-year basis. During the same period last year, the business posted ($0.28) EPS. Analysts anticipate that TG Therapeutics, Inc. will post -0.01 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.